ValuEngine upgraded shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) from a strong sell rating to a sell rating in a research note published on Monday.
Separately, Maxim Group assumed coverage on Interpace Diagnostics Group in a research report on Tuesday, August 15th. They issued a buy rating and a $5.00 price objective on the stock.
Shares of Interpace Diagnostics Group (NASDAQ:IDXG) traded down 0.7163% on Monday, reaching $1.3999. The company’s stock had a trading volume of 585,267 shares. The company has a 50 day moving average of $1.21 and a 200 day moving average of $1.75. The stock’s market capitalization is $31.03 million. Interpace Diagnostics Group has a 1-year low of $0.07 and a 1-year high of $14.25.
Interpace Diagnostics Group (NASDAQ:IDXG) last posted its earnings results on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. The firm had revenue of $3.86 million for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%.
An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Susquehanna International Group LLP bought a new position in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned 3.84% of Interpace Diagnostics Group at the end of the most recent quarter. Institutional investors and hedge funds own 7.58% of the company’s stock.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with our FREE daily email newsletter.